Publications

Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. The Lancet. Haematology. 2025. PMID: 40090350

Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, Smith KL, Wolff AC, Melisko ME, Shinn EH, Gallagher K, Angove R, Wheeler SB, Rocque GB. System-Level Transformations to Increase Patient Participation in Clinical Trials. JCO oncology practice. 2025. PMID: 40080789

Chari A, Bal S, Ailawadhi S, Krishnan A, Patel KK, Berdeja JG, Garfall A, Callander N, Banerjee R, Alsina M, Nooka AK, Dhakal B, Gasparetto C, Costello C. Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2025. PMID: 40175263

Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, Graff SL, Rugo HS. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. The oncologist. 2025. PMID: 40139260

Aggarwal R, Bhatt DL, Bonaca MP, Deck C, Lesogor A, Patel MR, Stroes ESG, Taub PR, Windecker S. Generalizability of VICTORION-1 PREVENT enrollment criteria to the United States population. American journal of preventive cardiology. 2025. PMID: 40230889

Atkinson TM, Mazumdar M, Van Hyfte G, Lee JY, Li Y, Lynch KA, Webb A, Holland SM, Lubetkin EI, Goldstone S, Einstein MH, Stier EA, Wiley DJ, Mitsuyasu R, Rosa-Cunha I, Aboulafia DM, Dhanireddy S, Schouten JT, Levine R, Gardner EM, Dunlevy H, Barroso LF, Bucher G, Korman J, Stearn B, Wilkin TJ, Ellsworth G, Pugliese JC, Cella D, Berry-Lawhorn JM, Palefsky JM. Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01). JCO oncology practice. 2025. PMID: 40048673

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim D, Mukherjee E, Krantz MS, Yao L, Johnson DB, Phillips EJ, Balko JM, Mohindra R, Quandt Z. irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets. medRxiv : the preprint server for health sciences. 2025. PMID: 40093199

Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Alan Paciorek, Paige Steiding, Claire Mulvey, Emily Bergsland. Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF. Endocrine Abstracts. 2025. PMID:

Alan Paciorek, Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Paige Steiding, Claire Mulvey, Emily Bergsland. Disparities in the rising incidence of early-onset neuroendocrine neoplasms. Endocrine Abstracts. 2025. PMID:

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative). Future oncology (London, England). 2025. PMID: 40045471

Rugo HS. Management of toxicities from antibody-drug conjugates. Clinical advances in hematology & oncology : H&O. 2025. PMID: 40153670

Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, DeZern AE, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths EA, Haque T, Jacoby M, Jonas BA, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness LJ, McCurdy SR, McMahon C, Odenike O, Osman A, Reddy VV, Sallman DA, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40073835

Johri S, Bi K, Titchen BM, Fu J, Conway J, Crowdis JP, Vokes NI, Fan Z, Fong L, Park J, Liu D, He MX, Van Allen EM. Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics. Nature communications. 2025. PMID: 40025015

Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, Enderling H, Schoenfeld JD, Brody JD, McGee HM, Mondini M, Kent MS, Young KH, Galluzzi L, Karam SD, Theelen WSME, Chang JY, Huynh MA, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji QH, Nguyen AT, Patel RB, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera TA, Ong IM, Herrera F, Menon H, Smart D, Ahmed J, Gartrell RD, Roland CL, Fekrmandi F, Chakraborty B, Bent EH, Berg TJ, Hutson A, Khleif S, Sikora AG, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet. Oncology. 2025. PMID: 40049206

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Volume 110 of Issue 3 Haematologica. 2025. PMID: 39540227

Gu D, Xia F, Vijayaraghavan M. Tobacco treatment and policies in mental health and substance use treatment facilities in the US. Drug and alcohol dependence. 2025. PMID: 40073805

Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G. Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40019493

Zhu X, Ding CC, Aggarwal RR. Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer. Current oncology reports. 2025. PMID: 40011325

Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025. PMID: 40016302

Inoue K, Liu M, Aggarwal R, Marinacci LX, Wadhera RK. Prevalence and Control of Diabetes Among US Adults, 2013 to 2023. JAMA. 2025. PMID: 40014316